Global Cardiac Biomarkers Market is Estimated to Reach $13 Billion by 2024, Says Accurize Market Research
Global Cardiac Biomarkers Market report published by Accurize Market Research forecast that the global market is expected to reach $13 billion by 2024; growing at a CAGR of 19.1% from 2017 to 2025. By geography, Asia Pacific and North America are expected to grow at a CAGR of XX% and XX%, respectively, during the forecast period.
To browse the complete report, visit at https://www.accurizemarketresearch.com/report/cardiac-biomarkers-market
Increasing diagnostic applications of biomarkers, growing R&D funding for pharma sector and biotech companies, rising number of CROs and low cost of clinical trials in developing countries to drive the growth of the market
Increasing diagnostic applications of biomarkers, growing R&D funding for pharma sector and biotech companies, rising number of CROs and low cost of clinical trials in developing countriesfuelsthe demand for the global cardiac biomarkers market.Furthermore,the high prevalence of cancer and new initiatives for researchalso boosts the growth of the market.
The global cardiac biomarkers market has been bifurcated on the basis of type, and geography. Type segment is bifurcated as safety biomarkers, efficacy biomarkers and validation biomarkers. By geography the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW).
Top players in the market
The key players operational in the market includes Abbott Laboratories, Danaher, Life Diagnostics Inc., Meridian Life Science Inc., Hoffmann-La Roche Ltd., Siemens Ag, Trinity Biotech Plc., Thermo Fisher Scientific, Spectral Medical Inc., and Health-Chem Diagnostics among others.
Head - Sales
Accurize Market Research
K-129, PC COLONY, HANUMAN NAGAR,